COPD Trial, Recruiting NCT06948487 Sponsor: Daewoong Pharmaceutical Co. LTD. Condition: COPD
Back to Copd

COPD Trial, Recruiting

NCT06948487
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 19 and 75 years old at the time of signing the consent form
  • You are already scheduled by your doctor to take Fexuclu tablets (fexuprazan) for an approved medical reason
  • You have at least one symptom that your doctor has decided needs medical treatment
  • You are able to understand the study information, have chosen to take part freely, and are willing to sign a consent form allowing use of your personal data

Who may not be able to join:

  • You have any medical reason that means you should not take Fexuclu tablets (fexuprazan), as listed in the official medication guidelines
  • Your doctor decides, for any other reason, that it would not be appropriate for you to take part in this study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jingun Kim, Dr., Masong Kim Internal Medicine Clinic

Phone: 82-10-2994-5887

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Daewoong Pharmaceutical Co. LTD.
Registry
ClinicalTrials.gov
Start date
17 June 2025
Est. completion
30 November 2025

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

The proportion of subjects with improvement in subjective symptoms

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov